Panlin Capital

Panlin Capital is an early-stage venture capital institution that focuses on technological innovation-driven consumption upgrade, with a particular emphasis on biotechnology and data intelligence applications. To date, the total valuation of Panlin Capital' invested projects exceeds $31 billion. In the field of biomedicine, based on biotechnology (Biotechnology), Panlin Capital specializes in investing in innovative biopharmaceutical companies focused on major disease treatments and high-end medical device companies aimed at import substitution. Early investments include biopharmaceutical enterprises such as CanSino Biologics (300601), RiboBio, Shengnuo Gene, Apollomics, GenFleet Therapeutics, Affinity Biosciences, Cothera, ABM, and Virogin Biotech, as well as medical device and service companies like Capricorn Medical (300639), Goldstone Bio, Antai Kangcheng, T-Insight, Langrui Healthcare, Oshine Medical, Beijing Kyoto Children's Hospital, and Capricorn Lab. In the consumer TMT sector, leveraging data intelligence (Data Intelligence Technology), Panlin Capital focuses on enterprise-level services and data intelligent equipment companies that drive intelligent and digital transformation in the supply side of consumer markets. Early investments include enterprise service firms such as Pingxin Technology (acquired by Meituan), Gonggui Home, Runya Information, Ebuy Industrial Products, Ziyun Tech, Tuya Tech, Xiguang Tech, Rayvision Tech, and InspireTech, along with data intelligent equipment companies like AoShi Tech (merged into Geely), ChuanTu Microelectronics, Tuya Tech, and Longbo Tech. Panlin Capital has also been a growth-stage investor in A-share listed companies including Toread (300005), GEOHIGHT Environmental Protection (603588), Oriental Fashion Driving School (603377), Junmeng Games (acquired by Fuchun Co., Ltd. 300299), Sunstory (acquired by Royal Group 002329), and XGIMI Technology (listed on the STAR Market). Currently, Panlin Capital has become a professional and influential technology venture capital firm in both biotechnology and data intelligence applications. Looking ahead, Fortune United Partners strives to be the best.